Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag. 

Last reviewed: 5 July 2017

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance